Tüdőrák: vizsgálatok itt: Románia
55 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.
- 3. fázisBefejeződöttStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Cluj-Napoca, Iași
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Cluj-Napoca, Craiova, Floresti, Suceava
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - 3. fázisBefejeződöttA Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Where
- Bucharest, Bucuresti, Cluj-Napoca, Craiova, Floresti, Timisoara
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01 - 2. fázisBefejeződöttNiraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- Where
- Cluj-Napoca
- Életkor
- 18 év and over
- People
- 44 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00 - 3. fázisTaking peopleA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
- Where
- Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Ovidiu, Timisoara
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Maia Biotechnology
See details and how to joinNCT06908304 · EU 2024-520164-33-00